Skip to main content
Roche's diffuse large B-cell lymphoma drug gains FDA approval

Roche unit Genentech's Polivy, or polatuzumab vedotin-piiq, has been approved by the FDA for use in combination with bendamustine and rituximab as a treatment for adult patients with relapsed or refractory diffuse large B-cell lymphoma who have had two or more previous therapies.

Full Story: